91037-65-9
基本信息
甘氨酸-天冬氨酸
精-甘-天冬-丝氨酸
精氨酸-甘氨酸-天冬氨酸-丝氨酸
精氨酰-甘氨酰-天冬氨酰-丝氨酸
H-精氨酸-甘氨酸-天冬氨酸-丝氨酸-OH
L-精氨酰甘氨酰-L-ALPHA-天冬氨酰-L-丝氨酸
精氨酰-甘氨酰-天冬氨酰-丝氨酸, ≥95%(HPLC)
(6S,12S,15S)-1,6-二氨基-12-(羧甲基)-15-(羟甲基)-1-亚氨基-7,10,13-三氧代-2,8,11,14-四氮杂十六烷-16-羧酸
RGDS peptide
ARG-GLY-ASP-SER
RGDS 1/2ACOH 2H2O
L-ARG-GLY-ASP-SER
Arg-Gly-Asp-Ser-OH
H-ARG-GLY-ASP-SER-OH
RGDS/ARG-GLY-ASP-SER
FIBRONECTIN INHIBITOR
Arg-Gly-Asp-Ser, >=98%
物理化学性质
| 熔点 | 183-187℃ |
| 密度 | 1.65±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | ≥21.65 mg/mL in H2O; insoluble in EtOH; insoluble in DMSO |
| 酸度系数(pKa) | 2.84±0.10(Predicted) |
| 形态 | 白色至类白色粉末 |
| 颜色 | White to off-white |
| 生物来源 | synthetic |
| 水溶解性 | Soluble in water at 1mg/ml |
| 序列 | H-Arg-Gly-Asp-Ser-OH |
| InChIKey | NNRFRJQMBSBXGO-CIUDSAMLSA-N |
| SMILES | N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P305+P351+P338 |
| WGK Germany | 3 |
| WGK Germany | 3 |
| 存储类别 | 11 - Combustible Solids |
应用领域
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
Arg-Gly-Asp-Ser价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-12290R | Arg-Gly-Asp-Ser Arg-Gly-Asp-Ser (Standard) | 91037-65-9 | 5 mg | 800元 |
| 2026/09/15 | HY-12290R | Arg-Gly-Asp-Ser Arg-Gly-Asp-Ser (Standard) | 91037-65-9 | 10 mg | 1300元 |
| 2026/09/15 | HY-12290R | Arg-Gly-Asp-Ser Arg-Gly-Asp-Ser (Standard) | 91037-65-9 | 25 mg | 2600元 |
常见问题列表
The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3 integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca 2+ ·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited. Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (K d 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA.
Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS. Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity.